Reply to Bexultan Kazybay and Yingqiu Xie’s Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, ...
Published in European Urology
Re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testoster...
Published in European Urology
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
...Published in European Urology
Tumour fraction, independent from cell-free DNA concentration and other clinical variables, is prognostic, with low-pass whole-genome sequencing profiles detecting abiraterone/enzalutamide-induced emerging genomic instability that is likely to be acquired as a result of tumour development.
Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy
Published in European Urology
Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin.
Published in European urology
Our understanding of the mechanism of bacillus Calmette-Guérin (BCG) in controlling urothelial carcinoma is still evolving. Studies have revealed a complex and multifaceted immune response. BCG-elicited adaptive antitumor immunity directed towards tumor antigens could have major implications for trial design. Copyright © 2020 European Association o...
Shockwave Lithotripsy Versus Ureteroscopic Treatment as Therapeutic Interventions for Stones of the Ureter (TISU): A Mul...
...Published in European Urology
This level 1 evidence highlights only a slight difference between ureteroscopy (URS) and shockwave lithotripsy (SWL), supporting SWL as an outpatient treatment without anaesthetic or theatre requirements, particularly relevant after COVID-19. While URS had higher stone clearance, both modalities appear suitable for primary treatment choice.
The impact of COVID-19 on the medium-term outcomes of urological cancer - International prospective 3 year follow up stu...
...Published in European Urology
Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU prostate cancer working group mu...
...Published in European Urology
CD38 in Advanced Prostate Cancers
...Published in European Urology
CD38 is expressed by phenotypically diverse prostate tumour-infiltrating immune cells (TIICs). CD38+ TIICs are associated with a worse prognosis and may be implicated in prostate cancer immune tolerance. Existing CD38-directed therapies merit evaluation in metastatic prostate cancer clinical trials.
Management of acute ureteric colic in a large tertiary centre during the initial COVID-19 pandemic - How did our practic...
Published in European Urology
